Cardiomyopathy Therapeutic Development and Pipeline Market Review H1 2015 Available at RnRMarketResearch.com

Share Article

RnRMarketResearch.com adds “Cardiomyopathy - Pipeline Review, H1 2015” to its store. The report provides an overview of the Cardiomyopathy’s therapeutic pipeline.

Cardiomyopathy Therapeutic Pipeline Market Review H1 2015

Cardiomyopathy Therapeutic Pipeline Market Review H1 2015

Past News Releases

RSS

The report “Cardiomyopathy - Pipeline Review, H1 2015” provides comparative analysis on the therapeutic development for Cardiomyopathy. Cardiomyopathy, any cardiac disease process that results in heart failure due to a decrease in the pumping power of the heart or due to an impairment in the filling of the cardiac chambers. Types of Cardiomyopathy are ischemic, dilated, hypertrophic and restrictive Cardiomyopathy. The report strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Complete report with TOC is available @ http://www.rnrmarketresearch.com/cardiomyopathy-pipeline-review-h1-2015-market-report.html .

The report also reviews key players involved in the therapeutic development for Cardiomyopathy and special features on late-stage and discontinued projects. Companies discussed in this Cardiomyopathy – Pipeline Review, H1 2015 report include Array BioPharma Inc., Beech Tree Labs, Inc., Bioheart, Inc., Celladon Corporation, Gilead Sciences, Inc., Kasiak Research Pvt. Ltd., LG Life Sciences, Ltd., miRagen Therapeutics, Inc., MyoKardia, Inc., Neurimmune Holding AG, Novartis AG, Nyken BV, Sanofi, Shire Plc, Stemedica Cell Technologies, Inc., Stempeutics Research Private Limited, Torrent Pharmaceuticals Limited and Vericel Corporation.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Drug Profiles mentioned in this report are AdipoCell, ARRY-797, binimetinib, CAP-1002, Cyndacel-M, Drug for Cardiomyopathy, Drugs to Activate Nrf2 for Diabetic Cardiomyopathy, Gene Therapy for Cardiomyopathy, Gene therapy to Activate mSCF for Ischemic Cardiomyopathy, Gene Therapy to Activate Smad7 for Hypertensive Cardiomyopathy and Kidney Fibrosis, GLP-1, GS-6615, ixmyelocel-T, JR-100, LC-280126, Mesenchymal Stem Cells, MGN-9103, Monoclonal Antibodies for Cardiovascular Diseases, MYK-461, NI-301, NYK-1112, perhexiline maleate, Recombinat Proten to Antagonize Interleukin-1 Receptor for Cardiomyopathy and Ischemia Reperfusion InjuryRefacell-DCM, Refacell-DCM, SHP-627, Small Molecule for Dilated Cardiomyopathy, Stempeucel and TRC-120038. Order a purchase copy of this report @ http://www.rnrmarketresearch.com/contacts/purchase?rname=356480 . (This is a premium report priced at US$2000 for a single user License.)

Featured News & Press Releases cover by this report include: Jan 29, 2015: Vericel Completes Patient Enrollment in Phase 2b ixCELL-DCM Clinical Study of Ixmyelocel-T 106, Nov 20, 2014: University of Pennsylvania Doses First Patient in Phase IIa Clinical Trial Using CardioCell's Stem Cell Therapy to Treat Chronic Heart Failure Due to Non-Ischemic Cardiomyopathy 106, Nov 12, 2014: Bioheart Announces First Intracoronary Implantation of Adipose Stem Cells in Azerbaijan 107, Oct 27, 2014: Celladon Corporation Announces Publication of Data From Its Stem Cell Factor Gene Therapy Program in Circulation Heart Failure 107, Aug 22, 2014: Treatment With Aastrom's Ixmyelocel-T Shown to Reduce Incidence of Major Adverse Cardiovascular Events in Patients With Ischemic Dilated Cardiomyopathy 108, Apr 02, 2014: FDA Grants IND Approval for Phase IIa Clinical Trial Using CardioCell's itMSC Therapy to Treat Dilated Chronic Heart Failure 109, Dec 19, 2013: Aastrom Biosciences Granted Composition-of-Matter Patent for Ixmyelocel-T in Australia 110, Dec 17, 2013: Capricor Therapeutics Cleared to Begin Phase II Portion of ALLSTAR Clinical Trial with CAP-1002 in Patients Following Heart Attack 110, Sep 16, 2013: Aastrom Clinical Trial Application for Phase 2b ixCELL-DCM Study of ixmyelocel-T Approved in Canada 111 and Apr 19, 2013: Aastrom Biosciences Announces First Patients Treated In IxCELL-DCM Clinical Study Of Ixmyelocel-T 111.

List of Tables
Number of Products under Development for Cardiomyopathy, H1 2015 10
Number of Products under Development for Cardiomyopathy - Comparative Analysis, H1 2015 11
Number of Products under Development by Companies, H1 2015 13
Number of Products under Investigation by Universities/Institutes, H1 2015 14
Comparative Analysis by Clinical Stage Development, H1 2015 15
Comparative Analysis by Early Stage Development, H1 2015 16
Comparative Analysis by Unknown Stage Development, H1 2015 17
Products under Development by Companies, H1 2015 18
Products under Development by Companies, H1 2015 (Contd..1) 19
Products under Investigation by Universities/Institutes, H1 2015 20
Assessment by Monotherapy Products, H1 2015 39
Number of Products by Stage and Target, H1 2015 40
Number of Products by Stage and Mechanism of Action, H1 2015 42
Number of Products by Stage and Route of Administration, H1 2015 44
Number of Products by Stage and Molecule Type, H1 2015 46
Cardiomyopathy Therapeutics - Recent Pipeline Updates, H1 2015 88
Cardiomyopathy - Dormant Projects, H1 2015 105

Explore more reports on Cardiovascular therapeutics industry at http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals/therapeutics/cardiovascular-therapeutics .

About Us:
RnRMarketResearch.com is an online database of market research reports offer in-depth analysis of over 5000 market segments. The library has syndicated reports by leading market research publishers across the globe and also offer customized market research reports for multiple industries.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Ritesh Tiwari
@RnRMR
since: 06/2012
Follow >
RnR Market Research
Like >
Follow us on
Visit website